Pharmaceutical Pricing and Medical Innovation
Other featured articles
How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?
If cost-sharing were based on net price it would provide meaningful financial relief to many Part D beneficiaries.
The Association Between Drug Rebates and List Prices
Drug rebates and list prices are positively correlated: On average, a $1 increase in rebates is associated with a $1.17 increase in list price.
Paying for Cell and Gene Therapies in Medicare
Join Schaeffer Center Director Dana Goldman in conversation with Jeet Guram and Kathy Buto about policy lessons learned and potential solutions to support innovation and patient access in cell and gene therapies.
Blood-Based Multicancer Tests Can Reduce Racial and Socioeconomic Cancer Health Disparities
Out of the 1.3 million individuals between the ages of 50-79 who are diagnosed with cancer, only 15% of those cases will be caught early. Aspen Institute and USC Schaeffer Center partnered for an expert discussion on early detection technologies.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.